Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Breast Cancer Research

Figure 2

From: PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer

Figure 2

PIK3CA/mTOR pathway (# 4EBP1 is inactivated by phosphorylation) a). Immunohistochemistry was performed for phosphorylated AKT, pS6 and p4EBP1. b) Outcome of immunohistochemical staining integrating PIK3CA mutation status. Numbers indicate the amount of cases showing positive immunohistochemical staining. Mutations are signified by (n*), with n = number of cases. mTOR, mammalian target of rapamycin.

Back to article page